Kite Reports Submission of sBLA to the US FDA for Tecartus in Adult Patients with R/R Acute Lymphoblastic Leukemia
Shots:
- The sBLA is based on data from the P- I/II ZUMA-3 trial in adult patients age ≥18 years old for the treatment of adult patients with r/r B-cell ALL
- The focus of the study is to evaluate the safety and efficacy in adult patients with r/r ALL
- If approved- Tecartus will be the 1st and only CAR T-cell therapy approved for adult patients. In July 2020- Tecartus received an accelerated approval from the US FDA for the treatment of r/r mantle cell lymphoma- based on ORR and DOR
Ref: BusinessWire | Image: BusinessWire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com